Citadel Advisors LLC Makes New Investment in Addex Therapeutics Ltd (NASDAQ:ADXN)

Citadel Advisors LLC bought a new position in shares of Addex Therapeutics Ltd (NASDAQ:ADXN) in the 4th quarter, HoldingsChannel.com reports. The fund bought 12,079 shares of the company’s stock, valued at approximately $85,000.

Addex Therapeutics Price Performance

NASDAQ:ADXN opened at $8.57 on Wednesday. The firm’s 50 day simple moving average is $7.82 and its 200 day simple moving average is $7.80. Addex Therapeutics Ltd has a one year low of $6.51 and a one year high of $13.27. The company has a market cap of $9.08 million, a PE ratio of -25.21 and a beta of 1.62.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.